当前位置： SCI文献检索 > JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY期刊下所有文献 > Ambrisentan therapy for pulmonary arterial hypertension.

Ambrisentan therapy for pulmonary arterial hypertension.

Abstract：

OBJECTIVES:The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH). BACKGROUND:Pulmonary arterial hypertension is a life-threatening and progressive disease with limited treatment options. Endothelin is a vasoconstrictor and smooth muscle cell mitogen that plays a critical role in the pathogenesis and progression of PAH. METHODS:In this double-blind, dose-ranging study, 64 patients with idiopathic PAH or PAH associated with collagen vascular disease, anorexigen use, or human immunodeficiency virus infection were randomized to receive 1, 2.5, 5, or 10 mg of ambrisentan once daily for 12 weeks followed by 12 weeks of open-label ambrisentan. The primary end point was an improvement from baseline in 6-min walk distance (6MWD); secondary end points included Borg dyspnea index, World Health Organization (WHO) functional class, a subject global assessment, and cardiopulmonary hemodynamics. RESULTS:At 12 weeks, ambrisentan increased 6MWD (+36.1 m, p < 0.0001) with similar and statistically significant increases for each dose group (range, +33.9 to +38.1 m). Improvements were also observed in Borg dyspnea index, WHO functional class, subject global assessment, mean pulmonary arterial pressure (-5.2 mm Hg, p < 0.0001), and cardiac index (+0.33 l/min/m2, p < 0.0008). Adverse events were mild and unrelated to dose, including the incidence of elevated serum aminotransferase concentrations >3 times the upper limit of normal (3.1%). CONCLUSIONS:Ambrisentan appears to improve exercise capacity, symptoms, and hemodynamics in patients with PAH. The incidence and severity of liver enzyme abnormalities appear to be low.

journal_name

J Am Coll Cardiol

journal_title

Journal of the American College of Cardiology

authors

Galié N,Badesch D,Oudiz R,Simonneau G,McGoon MD,Keogh AM,Frost AE,Zwicke D,Naeije R,Shapiro S,Olschewski H,Rubin LJ

doi

10.1016/j.jacc.2005.04.050

subject

Has Abstract

pub_date

2005-08-02 00:00:00

pages

529-35

issue

eissn

0735-1097

issn

1558-3597

pii

S0735-1097(05)01047-8

journal_volume

pub_type

临床试验,杂志文章,随机对照试验

在线工具

Ambrisentan therapy for pulmonary arterial hypertension.